TruCheck uses immunocytochemistry to identify intact circulating tumour cells in blood—whole cells shed from solid tumours into the bloodstream, often years before symptoms develop or conventional imaging can detect disease. The test can identify both the cancer type and the tissue of origin with high accuracy for most cancer histologies.

Sensitivity: 88% — The ability to identify people who do have cancer. Early signs are picked up in at least 88 out of every 100 cases where cancer is present. Specificity: 99% — The ability to identify people who do not have cancer. False positives are rare (1 in every 100 or less), meaning unnecessary investigations that follow are uncommon.

At the time of testing, no detectable circulating tumour cells from the 70+ cancers within scope were found in your blood. This is reassuring but represents a picture of that moment rather than a guarantee for the future. No conclusion should be drawn about cancers the test does not cover (blood/lymphatic cancers). We recommend repeating TruCheck annually as part of ongoing surveillance.

Circulating tumour cells were detected in your sample. For many cancer types, the report identifies the site with high accuracy. Your doctor telephones you personally, explains what it means, and arranges referral along an established pathway for specialist imaging (CT, MRI, ultrasound, endoscopy) to confirm and locate the primary tumour. Positive TruCheck is a flag requiring investigation, not a final diagnosis.

Following a negative result, we recommend repeating TruCheck annually, usually alongside a full health assessment. Annual screening establishes trends, detects emerging cancer signals, and identifies early disease progression. For cancer survivors or those with high family history, your doctor may recommend more frequent testing.

Yes. TruCheck is valuable for cancer survivors as a surveillance tool. After treatment and confirmed remission, annual TruCheck can detect early recurrence or new primary cancers. Early detection of recurrent disease significantly improves treatment outcomes. Discuss timing and frequency with your oncologist or private doctor based on your cancer type and treatment completion date.

Yes. Many patients arrange TruCheck through their own limited company or as part of an executive health programme. The cost of health screening provided by a company is normally an allowable business expense. HMRC rules allow an employer to provide one health screening assessment and one medical check-up per employee each year without creating a taxable benefit in kind. We invoice the company directly and can arrange screening for directors and staff on unified programmes. Your accountant should confirm the treatment that applies to your circumstances.

Different tools, different purposes. TruCheck detects molecular cancer biomarkers (circulating tumour cells). Full Body MRI shows structural imaging (tumours, masses, tissue changes). Both are complementary. TruCheck is faster, cost-effective, and non-invasive blood test. MRI provides high-resolution anatomical detail and finds lesions before they shed biomarkers. Many patients benefit from both: TruCheck as annual screening + MRI as baseline or targeted imaging if TruCheck is positive.

If you develop cancer symptoms at any point, seek medical attention urgently regardless of your prior TruCheck result. Symptoms warrant immediate investigation by your doctor or specialist. Do not wait for your next scheduled TruCheck. Every test is a snapshot in time and not a guarantee against future disease.

TruCheck complements but does not replace standard cancer screening programmes. Colonoscopy detects precancerous polyps (which TruCheck cannot find). Mammography detects early breast cancer (which TruCheck can find but mammography remains standard). Your doctor will discuss which screening modalities are appropriate for your age, risk profile, and personal history.